Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6393104 | 0.82 | KDM4C (0.51) | BCHEKDM4EMAPTPKMMEN1 | |
| Oxalic Acid SCHEMBL3546925 | 0.82 | BCHE (0.71) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL6380551 | 0.81 | BCHE (0.54) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL27572202 | 0.81 | GAA (0.49) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL6392446 | 0.79 | TBXA2R (0.54) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL6398415 | 0.78 | TBXA2R (0.53) | BCHEKDM4EMAPTPKMMEN1 | |
| Hydrochloric Acid SCHEMBL145663 | 0.78 | BCHE (0.46) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL27572201 | 0.77 | TBXA2R (0.44) | BCHEKDM4EMAPTPKMMEN1 | |
| SCHEMBL12634261 | 0.76 | CHRM4 (0.56) | BCHEMAPTMEN1KMT2A | |
| SCHEMBL21328340 | 0.75 | BCHE (0.55) | BCHEKDM4EMAPTPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059032-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011022518-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059032-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE | BAD, BAK1, CASP3 | BCHE 1788/4885KDM4E 1679/4885MAPT 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.